Rubella Treatment Market Outlook:
Rubella Treatment Market size was valued at USD 258.2 million in 2025 and is projected to reach USD 426.9 million by the end of 2035, rising at a CAGR of approximately 5.5% during the forecast period, i.e., 2026-2035. In 2026, the industry size of rubella treatment is estimated at USD 271.4 million.
The escalating patient population and continued efforts to eliminate rubella through immunization programs are key factors facilitating upliftment in the market. As evidence the article published by the World Health Organization in May 2024 found that rubella is the leading vaccine-preventable cause of birth defects, wherein 100,000 infants are born every year across all nations affected by congenital rubella syndrome (CRS). It also stated that around 18,000 cases were reported across 78 countries in 2022, thereby positively influencing market growth.
Furthermore, from a pricing perspective, CDC in September 2025 reported that rubella is suggested as part of the combined measles, mumps, and rubella vaccine, which is available under two main brands, M-M-RII by Merck and Priorix by GlaxoSmithKline. For pediatric use, the CDC contract price for M-M-RII is around USD 26.35 per dose, wherein Priorix is USD 26.33, making them nearly identical in public sector pricing. The private sector M-M-RII displayed higher costs at USD 97.99 per dose when compared to USD 95.20 for Priorix, reflecting affordability in terms of public programs.
